Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition
Vivos Therapeutics' Q3 2025 revenue rose 76% year-over-year, driven by the acquisition of The Sleep Center of Nevada (SCN). Despite a decline in gross margin to 58% and a 74% increase in operating expenses, the company plans to expand its sleep center model. Analysts rate the stock as a 'buy' with a 12-month price target of $6.50, 62% above its current price.
)
Overview
- Vivos Q3 2025 revenue rises 76% yr/yr, driven by SCN acquisition
- Company’s gross margin declines to 58% from 60% due to pricing discounts
- Operating expenses increase 74% due to SCN acquisition-related costs
Outlook
- Vivos expects near-term expenses to rise due to investments in SCN operations
- Company plans to expand sleep center model beyond Las Vegas
- Vivos anticipates seeing patients at new Michigan location by December
Result Drivers
- SCN ACQUISITION IMPACT - Vivos attributes 78% sequential revenue growth to the acquisition of The Sleep Center of Nevada
- STRATEGIC PIVOT - Co’s shift from dental distribution to direct medical affiliations drives revenue increase
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net -$5.4
Income mln
Q3 Gross $3.94
Profit mln
Q3 -$4.73
Operatin mln
g Income
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 2 “strong buy” or “buy”, 1 “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the medical equipment, supplies & distribution peer group is “buy”
- Wall Street’s median 12-month price target for Vivos Therapeutics Inc is $6.50, about 62% above its November 18 closing price of $2.47
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
